- Previous Close
0.5800 - Open
1.6700 - Bid --
- Ask --
- Day's Range
1.0400 - 1.7900 - 52 Week Range
0.3020 - 134.6800 - Volume
101,209,969 - Avg. Volume
1,659,245 - Market Cap (intraday)
3.191M - Beta (5Y Monthly) --
- PE Ratio (TTM)
0.02 - EPS (TTM)
57.0700 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
www.gribio.com4
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: GRI
View More
Performance Overview: GRI
Trailing total returns as of 2024-10-21, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRI
View MoreValuation Measures
Market Cap
1.70M
Enterprise Value
-4.51M
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-82.53%
Return on Equity (ttm)
-189.06%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.28M
Diluted EPS (ttm)
57.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
6.35M
Total Debt/Equity (mrq)
2.99%
Levered Free Cash Flow (ttm)
-3.87M